These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 20862393

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The therapeutic potential of GPR119 agonists for type 2 diabetes.
    Ohishi T, Yoshida S.
    Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
    Yoshida S, Tanaka H, Oshima H, Yamazaki T, Yonetoku Y, Ohishi T, Matsui T, Shibasaki M.
    Biochem Biophys Res Commun; 2010 Oct 01; 400(4):745-51. PubMed ID: 20816753
    [Abstract] [Full Text] [Related]

  • 7. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion.
    Yoshida S, Ohishi T, Matsui T, Shibasaki M.
    Biochem Biophys Res Commun; 2010 Sep 24; 400(3):437-41. PubMed ID: 20804735
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
    Shah U, Kowalski TJ.
    Vitam Horm; 2010 Sep 24; 84():415-48. PubMed ID: 21094910
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
    Shah U.
    Curr Opin Drug Discov Devel; 2009 Jul 24; 12(4):519-32. PubMed ID: 19562648
    [Abstract] [Full Text] [Related]

  • 12. 5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion.
    Kogure R, Toyama K, Hiyamuta S, Kojima I, Takeda S.
    Biochem Biophys Res Commun; 2011 Dec 09; 416(1-2):58-63. PubMed ID: 22079287
    [Abstract] [Full Text] [Related]

  • 13. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
    Yoshida S, Ohishi T, Matsui T, Tanaka H, Oshima H, Yonetoku Y, Shibasaki M.
    Biochem Biophys Res Commun; 2010 Nov 12; 402(2):280-5. PubMed ID: 20937249
    [Abstract] [Full Text] [Related]

  • 14. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.
    Hryciw DH, Patten RK, Rodgers RJ, Proietto J, Hutchinson DS, McAinch AJ.
    Expert Opin Investig Drugs; 2024 Mar 12; 33(3):183-190. PubMed ID: 38372052
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119.
    Chu ZL, Carroll C, Chen R, Alfonso J, Gutierrez V, He H, Lucman A, Xing C, Sebring K, Zhou J, Wagner B, Unett D, Jones RM, Behan DP, Leonard J.
    Mol Endocrinol; 2010 Jan 12; 24(1):161-70. PubMed ID: 19901198
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic application of GPR119 ligands in metabolic disorders.
    Yang JW, Kim HS, Choi YW, Kim YM, Kang KW.
    Diabetes Obes Metab; 2018 Feb 12; 20(2):257-269. PubMed ID: 28722242
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.